The neurobiology of addictive disorders

Clinical Neuropharmacology

Volumn 32, Issue 5, 2009, Pages 269-276

  Ross, Stephen ^a,b,c   Peselow, Eric ^c  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Addiction; Neurobiology; Pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; ACETYLCHOLINE; BACLOFEN; BUPRENORPHINE; CANNABINOID 1 RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DISULFIRAM; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DRONABINOL; ENDOCANNABINOID; GLUTAMIC ACID; HALOPERIDOL; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; NEUROTRANSMITTER; ONDANSETRON; OPIATE PEPTIDE; RIMONABANT; SEROTONIN; TIAGABINE; TIAPRIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANOREXINE; VARENICLINE; VIGABATRIN;

ADDICTION; ALCOHOLISM; CANNABIS ADDICTION; COCAINE DEPENDENCE; CONDITIONED REFLEX; DECISION MAKING; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMPULSE CONTROL DISORDER; MEMORY; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REINFORCEMENT; RELAPSE; REVIEW; REWARD; STRESS; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; VACCINATION; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; DOPAMINE; HUMANS; NERVE NET; NEURONAL PLASTICITY; REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 70349792617     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181a9163c     Document Type: Review

References (58)

1. Kalivas PW, O-Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166-180.
2. Volkow ND, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006;26: 6583-6588.
3. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-1413.
4. Paulas MP. Neural basis of reward and cravingVa homeostatic point of view. Dialogues Clin Neurosci 2007;9:379-387.
5. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414-1422.
6. Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006;12(12):559-566.
7. Koob GF. Neurobiology of addiction. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 4th ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2008:3-16.
8. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 1993;18(1):75-113.
9. Heidbreder C. Novel Pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol 2005;526:101-112. (Pubitemid 41744109)
10. Wise RA. Brain reward circuitry: insights from unsensed incentives. In: Graham AW, Schultz TK, Mayo-Smith MF, et al, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine Inc.; 2003:57-71.
11. Grant JE, Brewer JA, Potenza MN. The neurobiology of substance and behavioral addictions. CNS Spectr 2006;11(12):924-930.
12. Walsh SL, Cunningham KA. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berl) 1997;130:41-58.
13. Krystal JH, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003;169:215-233.
14. Yonezawa Y, et al. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 1998;341:45-56.
15. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-1352.
16. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 2004; 172:16-24.
17. Krupitsky EM, Neznanova O, Masalov D. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 2007;164:519-523.
18. Comer SD, Sullivan MA. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007;193(2):235-245.
19. Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addic Med 2007;1(3):115-125.
20. Alper KR, Lotsof HS, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999;8:234-242.
21. Krupitsky E, Grineko A. Psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997;29(2): 165-183.
22. Krupitsky E, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 2002; 23:273-283.
23. Ross S. Ketamine and addiction. Primary Psychiatry 2008;15(9):61-69.
24. Roberts DC, et al. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav 1980;12:781-787.
25. Wise RA. Action of drugs of abuse on brain reward systems. Pharmacol Biochem Behav 1980;13:213-223.
26. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994;2:244-268.
27. Horvitz JC. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 2000;96:651-656.
28. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997;275:1593-1599.
29. Kalivas PW. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007;9:389-397.
30. Weiss F, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 2001;937:1-26.
31. Nie Z, et al. Ethanol augments GABAergic transmission in the central amygdale via CRF1 receptors. Science 2004;303:1512-1514.
32. Shaham Y, et al. CP-154,526, a selective, non-peptide antagonist of the corticotrophin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998;137:184-190.
33. Deroche-Gamonet, et al. The glucocorticoid receptor as a potential target to reduce cocaine abuse. J Neurosci 2003;23:4785-4790.
34. Shaham Y, et al. The reinstatement model of drug relapse: history, methodology, and major findings. Psychopharmacology (Berl) 2003; 168:3-20.
35. Mcfarland K, et al. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 2004;24:1551-1560.
36. McFarland K, Kalivas PW. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2001;21: 8655-8663.
37. Di Cano P, Everitt BJ. Contribution of the ventral tegmental area to cocaine-seeking maintained by a drug-paired conditioned stimulus in rats. Eur J Neurosci 2004;19:1661-1667.
38. Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol 2008;154(2):261-274.
39. Kalivas PW, et al. Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci 2003;1003:169-175.
40. Xi ZX, et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 2002;303:608-615.
41. Baker DA, et al. Neuroadaptation in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003;6:743-749.
42. LaRowe S, et al. Cocaine desire is reduced by N-acetlcystein. Am J Psychiatry 2007;164:1115-1117.
43. Peters J, Kalivas PW. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) 2006;186:143-149.
44. London ED, et al. Orbitofrontal cortex and human drug abuse: functional imaging. Cerebral Cortex 2000;10:334-342.
45. Hester R, Garavan H. Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulated, and cerebellar activity. J Neurosci 2004;24:11017-11022.
46. Volkow ND, et al. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9: 557-569.
47. Volkow ND, et al. The addicted human brain: insights from imaging studies. J Clin Invest 2003;111:1444-1451.
48. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455-470.
49. Gonzales D, et al. Varenicline, an >4A2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
50. Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol 2007;12:133-151.
51. Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol 2007;21:9-28.
52. Kosten T, Owens MS. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005;108:76-85.
53. Modell JG, Mountz JM, Glaser FB, et al. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res 1993;17(2):234-240.
54. Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994;165(4): 515-523.
55. Thomasson HR, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet 1991;48:677-681.
56. McCance-Katz EF, Kosten TR, Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry 1998;43:540-543.
57. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003;13:469-475.
58. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63(12):1118-1126.